Trump launches TrumpRx website to deliver lower drug prices for Americans

UNITED STATES — On 5 February, 2026, President Donald Trump formally launched TrumpRx.gov, a government website aimed at helping Americans buy prescription drugs at steeply reduced prices. The platform aggregates discounted offers from pharmaceutical companies that have signed “most-favored-nation” pricing deals with the Trump administration.

During a White House event, Trump described the launch as a “very big deal,” stating, “People are going to save a lot of money and be healthy.”

Standing before a screen displaying TrumpRx.gov, Trump listed high-cost drugs that would be cheaper under the programme, including insulin, fertility medications, and GLP-1 weight-loss drugs such as Wegovy and Zepbound.

Trump was joined by key officials including Mehmet Oz, Robert F. Kennedy Jr., and Joe Gebbia, who helped present the site’s functionality in an infomercial-style rollout.

Gebbia demonstrated that patients can print digital coupons from the website or store them in digital wallets, highlighting offers like an 83% discount on a fertility drug. Oz emphasised, “All the hard work that the president and the administration have done now is yours, but you have to go check TrumpRx.gov.”

The TrumpRx initiative builds on a series of agreements reached between the White House and 16 pharmaceutical companies. These include Pfizer, Eli Lilly, Novo Nordisk, AstraZeneca, Sanofi, and others. The agreements are based on a “most-favoured-nation” (MFN) pricing strategy, ensuring that Americans pay no more than citizens in other developed countries.

In return, the administration pledged to suspend certain tariffs on the pharmaceutical industry. Trump first announced the Pfizer agreement on 30 September, 2025, followed by a series of additional deals through the end of the year.

Drug pricing examples from the platform include:

• Wegovy (injectable): US$199–350 per month (down from US$1,349).

• Zepbound: US$299–346 per month (down from US$1,088).

• Insulin Lispro: US$25 per vial.

• Gonal-F (fertility): US$168 per pen.

• Cetrotide: US$22.50 (down from US$316).

• Airsupra (asthma): US$201 (down from US$504).

The website currently lists 43 drugs and links users to either company-run pharmacies or third-party platforms such as GoodRx, which provides digital coupon integrations. A GoodRx spokesperson confirmed it is a key integration partner for the platform.

Importantly, TrumpRx does not sell medication directly. Rather, it aggregates pricing and purchase links for consumers who have valid prescriptions. The discounts are available only to cash-paying patients, and purchases made without insurance do not count toward insurance deductibles or out-of-pocket maximums.

This dynamic could complicate the benefit for patients with existing health plans. Though TrumpRx offers prices far below list value, many patients may ultimately pay less using their insurance once deductibles are met.

Nevertheless, for uninsured individuals — or for drugs like weight-loss medications that are not covered by many insurance providers — TrumpRx may offer a viable savings path.

Trump’s policy efforts began with a May 2025 executive order directing his administration to enforce MFN pricing. The administration then issued letters to 17 pharmaceutical companies on 31 July, 2025, demanding pricing changes within 60 days or face regulatory pressure.

By the end of December 2025, all but one company — Regeneron — had signed agreements with the White House. Regeneron, maker of Dupixent, remains in negotiations, according to MarketWatch.

Industry bodies have voiced concern. Alex Schriver, Vice President at Pharmaceutical Research and Manufacturers of America, warned in 2025 that importing foreign price controls “would undermine American leadership” and affect innovation. He urged the government to focus instead on reducing intermediary costs in the U.S. healthcare system.

While the administration claims TrumpRx will “end global price-gouging,” healthcare economists have cautioned that the site’s listed savings may exaggerate real-world benefits. The discounts are calculated against inflated list prices, not the negotiated rates often paid by insurers or pharmacy benefit managers.

Still, the launch signals a political and policy milestone for Trump, who is seeking to make affordability of prescription drugs a core part of his administration’s health agenda.

Future updates to the platform are expected to include more medications and broader integration with manufacturer websites. There are also indications that the administration will push for regulatory changes to allow insurance providers to incorporate TrumpRx pricing into standard coverage.